3 Volumes; Looseleaf; updated with supplements & revisions.
Abbott, “Abbott to Voluntarily Withdraw Meridia (Sibutramine) in the U.S.,” press release, October 8, 2010. ... Robert T. Reville, and Laura Zakaras, eds., Confidentiality, Transparency, and the U.S. Civil Justice System, New.
A collection of papers from the ninth Fulbright Colloquium held in September 1989.
Drug Product Liability
Gramling v. Mallett, 701 N.W.2d 523 (Wis. 2005) (risk contribution approach might apply in lead pigment action if facts were as alleged by plaintiffs). 127. Hymowitz v. Eli Lilly & Co., 539 N.E.2d 1069, 1078 (N.Y.) (“we choose to ...
Products Liability: Pharmaceutical Drug Cases
A.H. Robbins Co. , 90 Wash.2d 9 , 577 P.2d 975 , 977978 ( Wash . 1978 ) . 37 Second Circuit : Bravman v . Baxter Healthcare Corp. , 984 F.2d 71 , 75-76 ( 2d Cir . 1993 ) ( applying New York law ) ; Lindsay v .
It may also be necessary to overcome the development risk defence where this is pleaded.
You'll find this text indispensable for the comprehensive information it provides on the pharmaceutical industry. If you are involved with the healthcare system, you know that drug-induced injury cases are as complex as they are common.
Should FDA Drug and Medical Device Regulation Bar State Liability Claims?: Hearing Before the Committee on Oversight and Government Reform,...
Drug Injury: Liability, Analysis, and Prevention